Scribe Therapeutics
Berkeley, US · 3 known investors
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions. The company uses advanced engineering of natural CRISPR systems to create targeted genetic medicines.
Founders & leadership
BO
Benjamin OakesFounder & CEO
JA
Jennifer A. Doudna, PhDCo-founder, Scientific Advisor
BL
Benjamin L. Oakes, PhDCo-founder, President and CEO
DF
David F. Savage, PhDCo-founder, Scientific Advisor
BS
Brett Staahl, PhDCo-founder, VP of External Innovation
Investors · 3
In the news
- Early-stage Scribe wants to write IPO story even as investors favor derisked portfolios - BioSpacebiospace.com · 2026
- Scribe Therapeutics Files Nasdaq IPO With $180Mallsci.com · 2026
- SCTX IPO News - Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPOrenaissancecapital.com · 2026
- Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechsendpoints.news · 2026
- Sell or Invest in Scribe Stock Pre-IPOnasdaqprivatemarket.com · 2024
- Scribe Therapeutics - 2026 Funding Rounds & List of Investors - Tracxntracxn.com · 2021